<- Go Home

electroCore, Inc.

electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Market Cap

$45.0M

Volume

120.6K

Cash and Equivalents

$7.9M

EBITDA

-$12.7M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$25.7M

Profit Margin

86.04%

52 Week High

$19.49

52 Week Low

$4.16

Dividend

N/A

Price / Book Value

-40.06

Price / Earnings

-3.30

Price / Tangible Book Value

-40.06

Enterprise Value

$42.9M

Enterprise Value / EBITDA

-3.55

Operating Income

-$13.3M

Return on Equity

337.84%

Return on Assets

-39.11

Cash and Short Term Investments

$13.0M

Debt

$10.8M

Equity

-$1.1M

Revenue

$29.8M

Unlevered FCF

-$1.7M

Sector

Health Care Equipment and Supplies

Category

N/A

Company Stock Pitches